Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer
NEW YORK, NY, March 23, 2022 /24-7PressRelease/ — Manhattan BioSolutions, Inc, an emerging biotechnology company developing a new class of targeted immunotherapies for the treatment of advanced and metastatic cancers, has been awarded a grant from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT program). The UB CAT grant will enable early-stage preclinical characterization of novel monoclonal antibody-based therapies targeting immunomodulatory receptors highly expressed in hematological malignancies. This collaborative research will be conducted in partnership with the laboratory of Dr Dhaval Shah, Associate Professor at the Department of Pharmaceutical Sciences, University at Buffalo, whose cutting-edge research in protein therapeutics and pharmacokinetic-pharmacodynamic modeling has significantly impacted drug development field around the globe.
The new monoclonal antibody (mAb) being developed by Manhattan BioSolutions binds to a highly conserved lymphocyte surface receptor that senses the presence of various components from fungi, viruses, and bacteria. This protein functions to regulate T-cell activation and plays an important role in the development and progression of hematological cancers. The proposed project focuses on experimental validation of the new mAb, enabling generation of safe and highly efficacious antibody-drug conjugates directed against selected tumor antigen.
Dr Borys Shor, Chief Executive Officer, Manhattan BioSolutions, commented, “This new program will expand Manhattan BioSolutions’ current discovery pipeline focused on the unique biologic therapies at the intersection of innate, adaptive immunity and cancer. Our industry expertise in antibody- and antibody-drug conjugate development complements world-class research conducted by Dr Shah’ laboratory and thus strengthen our commitment to discover innovative medicines for patients in need.”
Dr Dhaval Shah added, “The primary benefit of this collaboration is the strong synergy between our teams based on the unique expertise in antibody discovery, translational pharmacology and pharmacokinetic modeling of novel biologics. Together, we will be in a strong position to fully validate the selected antibodies in preclinical experiments.”
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of immunotherapies that target microbial recognition and inflammatory signaling pathways for the treatment of advanced cancers and immune-mediated diseases. Manhattan BioSolutions leverages two innovative therapeutic modalities for drug discovery: biologic therapies that selectively destroy cancer cells while sparing healthy tissues and synthetic microbes — genetically engineered living drugs. The company has established partnerships with the Stony Brook University, The University at Buffalo, INSERM, EVQLV, and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT).
About UB CAT
The University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) is a project cost-sharing grant program funded by NYSTAR, Empire State Development’s Division of Science, Technology, and Innovation to drive the growth of life and health science businesses in New York State.
Follow Manhattan BioSolutions on Twitter
Contact for investor inquiries:
Jordana Lovett, PhD
Director of Investor Relations